S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
NASDAQ:SAGE

Sage Therapeutics News Headlines

$38.21
-0.61 (-1.57%)
(As of 01/21/2022 04:00 PM ET)
Add
Compare
Today's Range
$38.09
$39.66
50-Day Range
$37.06
$43.59
52-Week Range
$36.13
$91.75
Volume
561,259 shs
Average Volume
457,183 shs
Market Capitalization
$2.25 billion
P/E Ratio
3.05
Dividend Yield
N/A
Beta
1.75
Get Sage Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SAGE and its competitors with MarketBeat's FREE daily newsletter.

Media Mentions By Week

Sage Therapeutics Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

SAGE
News Sentiment

0.70

0.40

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

SAGE Articles
This Week

0

2

SAGE Articles
Average Week



Sage Therapeutics (NASDAQ:SAGE) News Headlines Today

SourceHeadline
MarketBeat logoStock Traders Purchase High Volume of Sage Therapeutics Call Options (NASDAQ:SAGE)
americanbankingnews.com - January 13 at 2:14 PM
MarketBeat logoSage Therapeutics, Inc. (NASDAQ:SAGE) to Post FY2026 Earnings of $14.91 Per Share, Piper Sandler Forecasts
americanbankingnews.com - January 13 at 7:20 AM
finance.yahoo.com logoSAGE Therapeutics Inc (SAGE): Hedge Funds Are Taking Some Chips Off The Table
finance.yahoo.com - January 12 at 5:41 PM
finance.yahoo.com logoSage Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022
finance.yahoo.com - January 4 at 9:53 AM
finance.yahoo.com logoSage Therapeutics’ Third Annual FutureCast Showcases Data from All Three Brain Health Franchises
finance.yahoo.com - December 14 at 10:35 AM
nasdaq.com logoSage Announces Presentation Of Analyses From Clinical Program Of Zuranolone In MDD
nasdaq.com - December 8 at 8:28 AM
finance.yahoo.com logoSage Therapeutics and Biogen Announce New Analyses from the LANDSCAPE Clinical Development Program of Zuranolone in MDD Presented at the American College of Neuropsychopharmacology (ACNP) Congress
finance.yahoo.com - December 8 at 8:28 AM
msn.com logoSage Therapeutics - Biogen Share One Year Zuranolone 50mg Data In Depression Patients
msn.com - December 1 at 2:42 PM
nasdaq.com logoSage Announces Positive, One-Year Zuranolone 50 Mg Data On Major Depressive Disorder
nasdaq.com - December 1 at 9:35 AM
nasdaq.com logoRSI Alert: Sage Therapeutics (SAGE) Now Oversold
nasdaq.com - November 30 at 2:02 PM
nasdaq.com logoSage Therapeutics Inc Shares Close in on 52-Week Low - Market Mover
nasdaq.com - November 30 at 12:17 AM
finance.yahoo.com logoSage Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
finance.yahoo.com - November 24 at 9:19 AM
finance.yahoo.com logoDeclining Stock and Solid Fundamentals: Is The Market Wrong About Sage Therapeutics, Inc. (NASDAQ:SAGE)?
finance.yahoo.com - November 23 at 12:26 PM
au.finance.yahoo.com logoEmerging Drugs for the Treatment of Postpartum Depression: A Focus on Recent Clinical Trials | DelveInsight
au.finance.yahoo.com - November 23 at 7:25 AM
benzinga.com logoWhat 8 Analyst Ratings Have To Say About Sage Therapeutics
benzinga.com - November 4 at 1:11 AM
benzinga.com logoHow Bad Are Sage Therapeutics's Earnings? | Return On Capital Employed
benzinga.com - November 2 at 2:12 PM
nasdaq.com logoSage Therapeutics, Inc.'s (NASDAQ:SAGE) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
nasdaq.com - November 2 at 2:12 PM
finance.yahoo.com logoSage Therapeutics Announces Third Quarter 2021 Financial Results and Highlights Pipeline and Business Progress
finance.yahoo.com - November 2 at 8:38 AM
finance.yahoo.com logoShould You Buy Sage Therapeutics (SAGE) Ahead of Earnings?
finance.yahoo.com - November 1 at 12:36 PM
msn.com logoSage Therapeutics, Inc. (SAGE) Expected to Beat Earnings Estimates: Should You Buy?
msn.com - October 26 at 9:00 PM
finance.yahoo.com logoThe Petri Dish: Sage, Biogen plan drug application; TV show gets FDA nod
finance.yahoo.com - October 21 at 12:40 PM
finance.yahoo.com logo15 Biotech and Pharmaceutical Stocks to Buy According to Palo Alto Investors
finance.yahoo.com - October 21 at 7:40 AM
benzinga.com logoWhat 7 Analyst Ratings Have To Say About Sage Therapeutics
benzinga.com - October 20 at 8:54 PM
finance.yahoo.com logoSage Therapeutics to Report Third Quarter 2021 Financial Results on Tuesday, November 2, 2021
finance.yahoo.com - October 20 at 8:54 PM
finance.yahoo.com logoSage, Biogen now plan to submit depression drug candidate to FDA in second half of 2022
finance.yahoo.com - October 20 at 10:54 AM
markets.businessinsider.com logoSage, Biogen To File New Drug Application To FDA For Zuranolone
markets.businessinsider.com - October 19 at 8:47 AM
marketwatch.com logoSage Therapeutics, Biogen to Seek FDA Approval of Zuranolone in 2nd Half of 2022
marketwatch.com - October 19 at 8:47 AM
finance.yahoo.com logoShould I Buy SAGE Therapeutics Inc (SAGE)?
finance.yahoo.com - October 18 at 5:45 PM
nasdaq.com logoNoteworthy Tuesday Option Activity: IHRT, IRBT, SAGE
nasdaq.com - October 6 at 12:35 PM
finance.yahoo.com logoSage Therapeutics and Biogen Announce Consistent Clinically Meaningful Data for Zuranolone Across the LANDSCAPE and NEST Clinical Development Programs Presented at the European College of Neuropsychopharmacology (ECNP) Congress
finance.yahoo.com - October 4 at 11:30 AM
finance.yahoo.com logoNoema Pharma appoints Jeffrey Jonas as Independent Chairman of the Board of Directors
finance.yahoo.com - October 4 at 6:30 AM
finance.yahoo.com logoSage Therapeutics Launches SageCitizen Social Impact Initiative
finance.yahoo.com - October 1 at 10:17 AM
nasdaq.com logoFirst Week of May 2022 Options Trading For Sage Therapeutics
nasdaq.com - September 24 at 2:40 PM
finance.yahoo.com logoSage Therapeutics Appoints Chris Benecchi as Chief Commercial Officer
finance.yahoo.com - September 21 at 9:22 AM
msn.com logoWhy Sage Therapeutics Shares Are Trading Higher Today
msn.com - September 15 at 5:56 PM
marketwatch.com logoSage Therapeutics Gets Fast-Track Designation for Huntington's Disease Treatment
marketwatch.com - September 15 at 7:55 AM
markets.businessinsider.com logoSage Therapeutics Gets Fast Track Designation For SAGE-718 From FDA - Quick Facts
markets.businessinsider.com - September 15 at 7:55 AM
finance.yahoo.com logoSage Therapeutics Receives Fast Track Designation for SAGE-718 for the Treatment of Huntington’s Disease
finance.yahoo.com - September 15 at 7:55 AM
msn.com logoCovid UK news – live: PM says booster vaccines going ahead as advisers set to approve jabs for children
msn.com - September 14 at 10:02 AM
au.finance.yahoo.com logoSage Therapeutics (NASDAQ:SAGE) shareholders have endured a 73% loss from investing in the stock three years ago
au.finance.yahoo.com - August 25 at 4:31 PM
nasdaq.com logoESML's Holdings Could Mean 19% Gain Potential
nasdaq.com - August 23 at 9:09 PM
finance.yahoo.com logoSage Therapeutics Inc (SAGE) Q2 2021 Earnings Call Transcript
finance.yahoo.com - August 11 at 1:28 AM
nasdaq.com logoTuesday 8/10 Insider Buying Report: SAGE, UNVR
nasdaq.com - August 10 at 3:16 PM
ca.finance.yahoo.com logoSage Therapeutics Inc (SAGE) President and CEO Barry E Greene Bought $1 million of Shares
ca.finance.yahoo.com - August 9 at 6:00 PM
nasdaq.com logoSage Therapeutics Enters Oversold Territory (SAGE)
nasdaq.com - August 6 at 3:13 PM
markets.businessinsider.com logoWhere Sage Therapeutics Stands With Analysts
markets.businessinsider.com - August 4 at 2:52 PM
msn.com logoSage Therapeutics Drops Two Zuranolone Depression Trials Deemed Unnecessary For Approval
msn.com - August 3 at 1:44 PM
nasdaq.com logoSage Therapeutics' (NASDAQ:SAGE) Shareholders Are Down 71% On Their Shares
nasdaq.com - August 3 at 1:44 PM
finance.yahoo.com logoSage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Lags Revenue Estimates
finance.yahoo.com - August 3 at 1:44 PM
msn.com logoBRIEF-Sage Therapeutics Inc - Now Expects Topline Data For Skylark Study In Mid-2022
msn.com - August 3 at 8:43 AM
Get Sage Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SAGE and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 1/22/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.